Research programme: protein vaccines - ApoVaxAlternative Names: ApoFasL; ApoVax104; ApoVax104-HPV
Latest Information Update: 30 Aug 2012
At a glance
- Originator ApoVax
- Class Protein-vaccines
- Mechanism of Action CD95 antigen inhibitors; Human papillomavirus E7 protein inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer; Cervical cancer; Human papillomavirus infections; Tuberculosis; Type 1 diabetes mellitus
Most Recent Events
- 13 Feb 2007 This compound is still in active development
- 11 Apr 2002 Preclinical trials in Cancer in USA (unspecified route)